Seaport Therapeutics: Borrowed Efficacy, Engineered Safety, And A Post-IPO Discount
Seaport Therapeutics offers CNS upside with Glyph technology, solid cash runway, and key Phase 2b data ahead. Read more on SPTX stock here. - Seaport Therapeutics leverages proprietary Glyph technology to enhance bioavailability and safety for CNS drugs, targeting MDD and GAD…